TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03893955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenous (IV) Infusion
Study: NCT01830933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BreastCARE
Description: Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
Study: NCT01681238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol group 2
Description: ensure SpO2≥ 92%, MAP 65-100 mmHg, HR \<100 bpm, Hb\> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protocol group 1
Description: The goal of this protocol is to ensure MAP\> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP \<8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
Study: NCT03822260

Intervention type: DIAGNOSTIC_TEST
Intervention: Bezmialem VAkif Unv. Ethical board
Description: If ıs any trials not convenient to Helsinki Agrement about Human research rules
Study: NCT00201019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative intervention
Description: Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
Study: NCT03337620

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tx360
Description: Tx360 used to deliver active and placebo drug interventions to SPG.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tx360
Description: Tx360 used to deliver active and placebo drug interventions to SPG.
Study: NCT05323747

Intervention type: OTHER
Intervention: Observation
Description: Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
Study: NCT02105233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brain mimicking fluid
Description: filled into the operation cavity during surgery for glioblastoma
Study: NCT00914134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa infusion
Description: Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
Study: NCT04346160

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer Test I
Description: Collection of tear fluid

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer Test I
Description: Collection of tear fluid

Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer Test I
Description: Collection of tear fluid
Study: NCT00908414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 40 mg
Description: Participants will receive TMC589337 40 mg in Session Ia of Panel 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 100 mg
Description: Participants will receive TMC589337 100 mg in Session IIa of Panel 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 200 mg
Description: Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
Study: NCT04066881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)
Description: 1. DNA-HIV-PT123 (see above)~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~3. MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine Group C: Saline placebo (weeks 0,4,24,48)
Description: Sodium Chloride (NaCl) for injection, 0.9%

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine Group C: Saline placebo (weeks 0,4,24,48)
Description: Sodium Chloride (NaCl) for injection, 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control PrEP:TDF/FTC once daily (weeks 0-26)
Description: Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control PrEP:TDF/FTC once daily (weeks 0-26)
Description: Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control PrEP:TDF/FTC once daily (weeks 0-26)
Description: Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental PrEP:TAF/FTC once daily (weeks 0-26)
Description: Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental PrEP:TAF/FTC once daily (weeks 0-26)
Description: Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental PrEP:TAF/FTC once daily (weeks 0-26)
Description: Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Study: NCT01089101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study: NCT00908414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 400 mg
Description: Participants will receive TMC589337 400 mg in Session IVa of Panel 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 40 mg
Description: Participants will receive TMC589354 40 mg in Session Ib of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 100 mg
Description: Participants will receive TMC589354 100 mg in Session IIb of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 200 mg
Description: Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 400 mg
Description: Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
Study: NCT03547271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group A, C, W-135, and Y conjugate vaccine
Description: Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-Hib vaccine
Description: Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-HB-Hib vaccine
Description: Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-Hib vaccine
Description: Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-Hib vaccine
Description: Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (13-valent)
Description: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (13-valent)
Description: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (10-valent)
Description: Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine (10-valent)
Description: Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: Measles, mumps, and rubella vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR vaccine
Description: Measles, mumps, and rubella vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: Measles, mumps, and rubella vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: Measles, mumps, and rubella vaccine
Study: NCT00908414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 AA mg
Description: Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
Study: NCT03212274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo a MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT00908414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 BB mg
Description: Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 CC mg
Description: Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 DD mg
Description: Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 EE mg
Description: Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 YY mg
Description: Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg
Description: Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg
Description: Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg
Description: Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg
Description: Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg
Description: Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 600 mg
Description: Participants will receive TMC310911 600 mg in Panel 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
Study: NCT00333710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy
Description: Individual face-to-face contact with educational and goal setting components

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: Individual telephone contact with educational and goal setting components
Study: NCT03420339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant
Description: The stimulants used must meet FDA dosage guidelines for age.
Study: NCT01735149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kochujang Pills
Description: Kochujang Pills (34.5g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (34.5g/day)
Study: NCT01707888

Intervention type: PROCEDURE
Intervention: Thoracoscopy/VATS
Description: Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
Study: NCT04385433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPERIMENTAL ARM
Description: Patients in the experimental arm will receive:~* Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL GROUP
Description: Patients in the standard arm will receive:~* Daily placebo during 12 months (placebo initiation: first day of radiotherapy)~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions).

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)
Description: Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)
Description: Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
Study: NCT04423640

Intervention type: OTHER
Intervention: Active COVID-19 disease
Description: Adult patients admitted to the UMAE Specialty Hospital of CMN SXXI with a diagnosis of COVID-19. The diagnosis must be corroborated by the RT-PCR test.
Study: NCT03034096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Maintenance of general anesthesia with propofol infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volatile Agent
Description: Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
Study: NCT01115777

Intervention type: OTHER
Intervention: Quality of Life surveys completed at specified timepoints
Description: Quality of Life surveys (no treatment)
Study: NCT01992913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated Cognitive Behavioral Therapy
Description: Novel CBT paradigm for schizophrenia/schizoaffective disorder

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation (CCR)
Description: Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
Study: NCT04575441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with pilates ball
Description: Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
Study: NCT02975817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hibler's
Description: Passive body heat retention using multiple-layer tight wrapping of patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm Air
Description: Active, convective warming of patient using warm air blanket
Study: NCT01264809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific consultation for physical activity counseling
Description: Specific consultation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation for physical activity counseling
Description: Specific consultation
Study: NCT01945983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early norepinephrine
Description: Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
Study: NCT02899247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surface sealant
Description: Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~* The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No surface sealant
Description: Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).
Study: NCT02908984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific neck rehabilitation
Description: Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and vestibular rehabilitation, included oculomotor function if indicated, and general exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard primary health care
Description: The treatment may include pharmacological medication, chiropractic and physiotherapy or no active treatment
Study: NCT00713271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Low dose~Dry powder for inhalation, o.d., 1+12 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: intermediate dose~Dry powder for inhalation, o.d., 1+12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: high dose~Dry powder for inhalation, o.d., 1+12 days
Study: NCT01105312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole